未治療の黒色腫におけるニボルマブとイピリムマブの併用療法または単剤療法

Larkinら（Sun）はこの問題を研究しました。

www.synapsesocial.com/papers/6991393d73f006927f3bd812 — DOI: https://doi.org/10.1056/nejmoa1504030

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma· 2015 · 2,759 citations
2. Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation· 2014 · 5,333 citations
3. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).· 2014 · 137 citations
4. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors· 2010 · 1,865 citations
5. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib· 2014 · 2,642 citations